Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Pharmacokinetic, Pharmacodynamic, and Long-term Safety Study of Subcutaneous Benralizumab in Children with Severe Eosinophilic Asthma
2019-004638-40Phase 3
- Sponsor
- AstraZeneca
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Primary endpoint: Pharmacokinetics of benralizumab.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2019-004638-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004638-40.